Floatz logo

SODIUM ZIRCONIUM CYCLOSILICATE

Duchenne Muscular Dystrophy

Ohio State UniversitySmall moleculePhase 3Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
81/ 100

Competitive context

39 Active assets in the Duchenne Muscular Dystrophy cohort.

Asset / SponsorPhaseRating
Viltolarsen
NS Pharma, Inc.
Phase 4BBB
Golodirsen
Rare Disease Research, LLC
Phase 4BB
Delandistrogene Moxeparvovec
Sarepta Therapeutics, Inc.
Phase 3BB
Avi-4658
Sarepta Therapeutics, Inc.
Phase 3BB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Anne M. Connolly
Phase 4BB

View all 50 →

Same molecule, other indications

SODIUM ZIRCONIUM CYCLOSILICATE is also rated in:

Metabolic SyndromeDormant
B
Indicative ·
57 / 100
View asset →
HypertensionDormant
CCC
Indicative ·
54 / 100
View asset →
Endothelial DysfunctionDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →